Mukka Proteins IPO: Key dates, fund use, FY22 revenue

What’s happening with Mukka Proteins’ IPO

Karnataka-based Mukka Proteins Limited is moving through the IPO process after receiving the Securities and Exchange Board of India’s (SEBI) go-ahead and completing its public issue window. The company manufactures fish protein products and exports to over 20 countries. As per the draft red herring prospectus (DRHP) referenced in updates, the IPO is an entirely fresh issue of up to 8 crore equity shares, with a face value of Re 1 each. The equity shares are proposed to be listed on both the BSE and NSE.

The sequence matters because SEBI’s “observation letter” is treated as the regulator’s nod for an issuer to proceed with the public issue. In Mukka Proteins’ case, the observation letter is dated October 30, following a refiling of draft papers in June. Separately, the company is also finalising share allotment after the IPO, with allotment status expected on Tuesday, March 5.

SEBI nod and the observation letter

Mukka Proteins obtained SEBI’s observation letter on October 30, according to regulatory updates cited in the coverage. In SEBI’s terminology, this observation letter indicates the company can launch its public issue. The company had refiled its draft IPO papers with the regulator in June before receiving the observation.

This approval process is significant for issuers because it signals that SEBI’s review of the draft offer document has reached a stage where the company can move ahead with the issue, subject to final steps and market conditions. The updates also note that Mukka Proteins had earlier filed draft papers in March 2022, but shelved its IPO plan at the time and withdrew those papers.

Issue structure: fresh issue only

The IPO comprises only a fresh issue of up to 8 crore shares, with no offer-for-sale component mentioned in the provided details. That means the proceeds are intended to go to the company rather than to existing shareholders selling their stake. The face value of the equity shares is Re 1.

Market sources cited in the updates indicated the IPO size could be between Rs 175 crore and Rs 200 crore. This range is presented as market-sourced commentary rather than a final, confirmed size in the company’s documents.

How Mukka Proteins plans to use the IPO proceeds

The DRHP-linked updates lay out three broad uses of net proceeds. The company proposes to deploy up to Rs 120 crore towards working capital requirements. It also plans to invest up to Rs 10 crore in its associate, Ento Proteins Private Limited, and fund its working capital requirements. Any remaining proceeds are intended for general corporate purposes.

Working capital is typically a key requirement for manufacturing and export-oriented businesses, where cash cycles can be driven by inventory, receivables, and commodity-linked input costs. The draft paper extracts provided do not include further line-item breakups beyond these heads.

Allocation split across investor categories

The issue allocation bands highlighted in the draft paper extracts set clear limits and minimums across investor categories. Not more than 50% of the issue shall be available for allocation to qualified institutional buyers (QIB). Not less than 15% shall be available for allocation to non-institutional bidders (NIB). Not less than 35% shall be available for allocation to retail individual bidders.

These bands indicate the intended mix of institutional and non-institutional participation, while retaining a meaningful share for retail investors.

Business snapshot: products and export footprint

Mukka Proteins is described as a manufacturer of fish meal, fish oil, and fish soluble paste. Another description in the provided text notes it manufactures and exports fish proteins to over 20 countries. These details position the company in the fish protein and marine-products value chain, with international exposure.

The refiling coverage also described Mukka Proteins as leading India’s fish protein industry, though the extracts do not provide market share numbers or competitor comparisons.

Financial data cited in the DRHP coverage

One financial metric explicitly cited in the provided text is revenue for FY22. The DRHP coverage states the company made Rs 770.5 crore in revenue in FY22, up 27.6% year-on-year. No other profit, margin, or cash flow numbers are included in the provided material.

Because this number is specifically attributed to the DRHP coverage, it provides a reference point for scale, but it does not by itself indicate profitability or sustainability without additional disclosures.

Key dates: IPO window and allotment check

The IPO opened on February 29 and closed on March 4, as stated in the updates. The allotment status is expected to be announced on Tuesday, March 5. Investors can check the status on the BSE website or on the registrar’s website, as referenced in the allotment-related update.

The provided details do not include the IPO price band, subscription figures, or listing date.

Intermediaries and listing venues

Fedex Securities Private Limited is named as the sole book-running lead manager for the issue. Cameo Corporate Services Limited is the registrar of the offer. The equity shares are proposed to be listed on the BSE and NSE.

These entities play distinct roles in the IPO process: the lead manager runs the book-building and coordinates the issuance, while the registrar handles application processing and allotment-related records.

Snapshot table: issue structure and funds deployment

Timeline table: filings, approvals, and IPO process

Why the details matter for investors

The disclosed proceeds plan highlights working capital as the largest stated use (up to Rs 120 crore), which can be important for capacity utilisation and smoother operations in product manufacturing and exports. The proposed investment of up to Rs 10 crore into associate Ento Proteins Private Limited is another explicit use, along with general corporate purposes.

For investors tracking the post-issue process, the allotment timeline and the instruction to check status on the BSE or registrar’s website are the practical next steps mentioned. Beyond that, the provided information sets the framework of the issue, the regulatory clearance, and the basic business and revenue scale disclosed from FY22.

Closing note

Mukka Proteins’ IPO process, as described in the provided updates, includes SEBI’s observation letter dated October 30, a fresh-issue structure of up to 8 crore shares, and a proceeds plan anchored around working capital and a small associate investment. The company’s allotment status is expected on Tuesday, March 5, with updates available through the BSE or the registrar’s portal.